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Abstract  
BACKGROUND: Besides the conventional therapy for heart failure, the diuretics, cardiac 
glycosides and ACE-inhibitors, current pharmacotherapy includes beta-blockers, mainly because of 
their pathophysiological mechanisms upon heart remodeling.  
AIM: The study objective was to assess the cardiovascular mortality in the beta-blocker therapy 
group and to correlate it with the mortality in the control group as well as to correlate the combined 
outcome of death and/or hospitalization for cardiovascular reason between the two groups.  
MATERIALS AND METHODS: The study included 113 chronic heart failure patients followed up 
for a period of 18 months. The therapy group received conventional therapy plus the target dose of 
beta blockers, and the control group received the conventional therapy only. The therapy group was 
divided in three separate subgroups in terms of the type of beta-blocker (Metoprolol subgroup, 
Bisoprolol and Carvedilol subgroup). To compare the mortality and the combined outcome, the 
RRR (relative risk reduction) and NNT (number needed to treat) were used, as well as the survival 
analysis by Kaplan-Meier.  
RESULTS: The results showed the following: in regards of the cardiovascular mortality, the relative 
risk for death in the therapy group was 34%, which, though statistically not significant, is of great 
clinical significance. In regards of the combined outcome (death and/or number of hospitalizations) 
the results showed a RRR of 40% in the therapy group compared to the control group, which is 
statistically highly significant.  
CONCLUSION: The study confirmed that patients with stable chronic heart failure, treated with 
optimal doses of beta-blockers, show a significant reduction of the risk from death as well as 
combined outcome (death and/or number of hospitalizations). 
 
 
 
 
 
Introduction 
 
Heart failure is a pathophysiological condition 
when the abnormal heart function results in a failure of 
the heart to achieve blood output adequate to meet 
the requirements of the tissue metabolism. 
In condition of heart failure as a response to 
the heart dysfunction, several neuro-endocrine 
systems are activated, as well as the sympathetic 
nervous system. Norepinephrine and plasma-
catecholamine levels are increased and correlate with 
mortality rate, but the density of myocyte beta-1 
receptors is lowered in heart failure patients. Beta-
blockers inhibit the activity of norepinephrine and 
enhance the density of beta-1 receptors. By lowering 
the heart rate they lower the oxygen demand, prolong 
the diastole, resulting in a better myocardial perfusion 
and less malignant arrhythmias. They protect the 
heart of the direct cardiotoxicity of the catecholamines 
[1, 2]. They also suppress several activated 
neurohumoral systems in heart failure: rennin-
angiotensine system and endothelyne-1 system, a 
powerful vasoconstrictor [3]. 
Metoprolol and Bisoprolol are beta-1 
selective, and Carvedilol is a potent antagonist of 
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beta-1, beta-2 and also alfa-1 receptors. It defers from 
the other beta-blockers with the effect upon the 
polymorphonuclear cells and its antioxidant activity 
[4]. 
Beta–blockers are recommended for 
treatment of all patients with stabile heart failure from 
ischemic or non-ischemic etiology and reduced left 
ventricular ejection fraction in NYHA Class II to IV, as 
a standard therapy, including ACE-inhibitors and 
diuretics. 
Despite their long term benefit they can make 
an initial worsening of the symptoms, and therefore, 
we should start their application carefully, starting with 
a low dose and gradually raising it to the target level 
[5].  
The aims of the study were: to assess 
mortality rate in the group treated with the target dose 
of beta-blockers (the therapy group), compared with 
the group on conventional therapy (the control group). 
To compare the combined outcome (mortality and/or 
number of hospitalizations from cardiovascular 
reasons) between the two groups; to compare 
mortality as well as the combined outcome, regarding 
different types of beta-blockers in the therapy group 
(Metoprolol, Bisoprolol and Carvedilol); and to 
compare the mortality of each of the subgroups from 
the therapy group with the mortality in the control 
group.  
 
 
Material and Methods 
 
One hundred and thirty five patients with 
verified heart failure were investigated in the 
Outpatient department of the Cardiology Clinic in a 
period of two years. Out of 135, 113 patients 
underwent a complete investigation, and 22 of them 
were excluded from the study due to a worsening of 
the condition in the titration period. 
The follow up period of these 113 patients 
was 18 months. The minimum follow up period was 3 
months. The patients were divided in 2 groups, 
statistically not different in age and gender. The first 
group was treated by conventional therapy and target 
dose of beta-blocker (the therapy group), and the 
second by conventional therapy only (the control 
group).  
The therapy group was divided in 3 
subgroups according to the type of beta-blocker: a 
subgroup with Metoprolol, Bisoprolol and Carvedilol. 
Inclusion criteria: Age 40-70 years; Verified 
stable chronic heart failure: clinically according to the 
classification of the NYHA Functional Class from II –
IV, and by echocardiography with a confirmed ejection 
fraction (EF%) of 45% or less. 
The patient was required to be stable more 
than one month before included in the study. 
The investigation included: complete 
laboratory analyses every 3 months, 
electrocardiogram once a month, one and two-
dimensional transthoracic echocardiography every 3 
months. 
We compared mortality and the combined 
outcome between the two groups. To simplify the 
combined outcome we quantified this parameter by 
scoring other parameters taking part in it: (1) Number 
of hospitalizations (each hospitalization is scored by 
1); and (2) number of acute attacks of chronic heart 
failure (each attack is scored by 1). 
Table 1: Clinical and laboratory parameters for the total patient 
population (control and therapy group)  
Variable n/M  SD 
 Gender: men 
              women  
91 (80.5%) 
22 (19.5%) 
Age 57.35  8.6 
Weight (in zero time) - kg 76.18  11.6 
Weight (end of follow up) kg 70.81  12.3 
BMI (in zero time) kg/m
2
 26.11  2.8 
BMI (end of follow up) 24.4  12.5 
Htc (in zero time) vol% 0.39  0.05 
Htc (end of follow up) 0.37  0.05 
Scr (mol/l) 84.53  8.4 
Alb (g/l) 44.01  3.1 
Total. lipids (g/l ) 8.87  1.3 
HDL (mmol/l) 1.13  0.2 
LDL (mmol/l) 3.51  0.7 
Triglicerids (mmol/l) 1.53  0.5 
Na (mmol/l) 141.7  2.6 
K (mmol/l) 4.65  0.4 
ECG-zero time 1.66  1.15 
ECG-end of follow up 1.82  1.17 
EF % (zero time) 36.79  6.6 
EF % (end of follow up) 37.3  8.3 
EF% 1.17  6.8 
NYHA-FC(zero time) 3.27  0.7 
NYHA-FC(end of follow up) 2.55  0.9 
NYHA score 0.35  0.55 
Number of hospitalizations 1.0  1.26 
 Number of attacks of AHF 0.57  0.98 
SBP (mmHg) 98.45  15.9 
DBP (mmHg) 65.25  9.7 
Diagnosis: Ischemic 
  Non-ischemic HF 
53 (46.9%) 
60 (53.1%) 
Mortality 15 (13.2%) 
 
The study was clinical, prospective, 
interventional and controlled. We investigated 38 
variables and compared the data of the 2 groups at 
the beginning of the follow up (the zero time) and at 
the end of follow up, using Student t-test for numerical 
and Chi square test for nominal parameters. To 
compare the variables of interest between the three 
subgroups in the therapy group, we used ANOVA-one 
way test. We calculated the relative risk reduction and 
the number needed to treat to prevent the outcome in 
one patient (RRR and NNT) for the variables of the 
primary objective (mortality and the combined 
outcome-mortality and number of hospitalizations from 
cardiovascular causes). We made an analysis of the 
complete survival of all the groups and compared the 
survival between the control and therapy group and all 
the therapy subgroups separately with the Kaplan-
Meier method. A p value of < 0.05 was taken to be 
statistically significant. 
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Results 
 
Out of a total of 113 patients with chronic 
heart failure with NYHA-FC II–IV in a stable clinical 
condition, 60 were with a non-ischemic and 53 with 
ischemic heart failure. Ninety one of them were men 
and only 21 women (81.5% and 19.55% respectively), 
with a mean age of 57.3 ± 8.6 years. During the follow 
up the total mortality was 15 (13.2%).  
The total patient population is divided in 2 
groups, control and therapy group. The therapy group 
is divided in 3 subgroups, Metoprolol, Bisoprolol and 
Carvedilol. 
Table 2: Comparison of the parameters between the group of 
patients who died and the survived ones  
Parameters Survived n=98 
M  SD 
Dead n=15 
M  SD 
P = 
Weight - zero time (kg) 77.86  12.55 76.46  9.93 0.68 
Weight - end of follow up  72.54  11.74 69.33  11.65 0.32 
Htc - zero time (vol%) 0.396  0.5 0.402  0.4 0.64 
Htc end of follow up 0.377  0.5 0.366  0.4 0.49 
Scr (mol/l) 84.47  8.41 88.96  6.11 0.49 
Alb (g/l) 44.28  2.67 43.56  4.73 0.39 
Tlip (g/l) 8.82  1.22 8.84  1.24 0.96 
HDL(mmol/l) 1.22  0.89 1.14  0.22 0.74 
LDL (mmol/l) 3.47  0.63 3.47  0.66 0.98 
Tg (mmol/l) 1.55  0.47 1.60  0.55 0.70 
Na (mmol/l) 141.82  2.45 140.65  3.52 0.10 
K (mmol/l) 4.55  0.43 4.80  0.40 0.04 
EF% zero time 36.39  7.07 34.13  5.57 0.23 
EF% end of follow up 38.16  7.86 31.53  8.74 0.003 
EF% 1.74  6.26 2.60  8.82 0.02 
N
o
 Hospitalizations  0.86  1.00 1.86  1.50 0.001 
No. AHF  0.40  0.71 1.60  1.63 0.000004 
NYHA-FC zero 3.16  0.71 3.93  0.25 0.00007 
NYHA-FC end 2.33  0.75 3.93  0.25 0.00000 
NYHA score 0.25  0.50 1.00  0.37 0.000000 
SBP (mmHg) 104.83  15.21 82.30  10.40 0.000000 
DBP (mmHg) 68.95  9.04 54.44  6.69 0.000000 
Age 57.20  8.72 58.33  7.79 0.637 
  
When comparing the parameters in the total 
population group between the survived and the 
patients who died, at zero time and at the end of the 
follow up, there was a statistically lower ejection 
fraction at the end of the follow up in the group of the 
patients who died, as well as lower EF%, higher 
number of hospitalizations, more frequent attacks of 
acute heart failure, higher NYHA-FC at the beginning 
and at the end of the follow up and also higher NYHA-
score at the end of follow up, but regarding systolic 
and diastolic blood pressure, the values were 
statistically lower in the group of patients who died.  
Table 3: Comparison of outcome between the control and the 
therapy group  
a) Mortality 
CER EER RR 95%CI RRR% X
2
 NNT 
6/34 
0.17 
9/79 
0.113 
0.66 0.21 - 1.96 34% R=0.37 17.5 
b) Combined outcome 
CER EER RR 95%CI RRR% X
2
 NNT 
29/34 
0.85 
41/79 
0.51 
0.6 0.33 - 1.13 40% R=0.0008 3.03 
 
CER - Control event rate; EER - Experimental event rate; RR - Risk ratio; RRR - 
Relative risk reduction; NNT - Number needed to treat. 
 
CER = the number of patients who died 
divided by the number of the patients in the control 
group. 
EER = the number of patients who died 
divided by the number of the patients in the therapy 
group. 
95%CI (confidence interval) is the interval (the 
borders) between the events. 
CER= n (events)/total n EER= n (events)/total n 
RR= EER/CER RRR %= (CER-EER)/CER x 100 
NNT= 1/(CER-EER) 
Regarding mortality rate of the patients with 
the target dose of beta-blockers, compared to the 
control group, there wasn’t any statistically significant 
difference (Chi square test), but the RRR%, although 
the value of 34% was also statistically not significant, 
it had a substantial clinical value.  
Regarding the combined outcome (mortality 
and/or hospitalization), the therapy group showed a 
statistically significant improvement (p < 0.0008). 
RRR% was 40% and NNT was 3.03, which indicates 
that if we treat 3 patients with a target dose of beta-
blockers, we might prevent the combined outcome in 
one patient. 
Table 4: Comparison of outcome between the control group 
and the Metoprolol subgroup  
a) Mortality 
CER EER RR 95%CI RRR% H
2
 NNT 
6/34 
0.17 
4/29 
0.13 
0.76 0.2 - 3.04 24% 0.68 25 
b) Combined outcome 
CER EER RR 95%CI RRR% X
2
 NNT 
29/34 
0.85 
20/29 
0.68 
0.80 0.38 - 1.72 20% 0.0007 5.8 
 
The mortality in the 3 therapy subgroups did 
not show a statistically significant difference when 
compared to the control group, but the combined 
outcome (mortality and/or hospitalizations) in the 3 
subgroups, separately, when compared to the control 
group, showed a statistically significant improvement.  
Table 5: Comparison of outcome between the control group 
and the Bisoprolol subgroup 
a) Mortality 
CER EER RR 95%CI RRR% X
2
 NNT 
6/34 
0.17 
3/24 
0.12 
0.70 0.16 - 3.12 30% 0.58 20 
 b) Combined outcome 
CER EER RR 95%CI RRR% X
2
 NNT 
29/34 
0.85 
14/24 
0.58 
0.68 0.3 - 1.56 32% 0.022 3.7 
  
Regarding RRR% and NNT, there was a 
major improvement for both outcomes in all the 3 
subgroups of beta blockers, but the Carvedilol 
subgroup showed highest values for RRR% (mortality 
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- 56%, and the combined outcome - 38%) (Table 4, 5, 
6). 
Table 6: Comparison of outcome between the control group 
and the Carvedilol subgroup  
a) Mortality 
CER EER RR 95%CI RRR% X
2
 NNT 
6/34 
0.17 
2/26 
0.076 
0.44 0.08 - 2.34 56% 0.22 11 
b) Combined outcome 
CER EER RR 95%CI RRR% X
2
 NNT 
29/34 
0.85 
14/26 
0.53 
0.62 0.28 - 1.43 38% 0.0079 3.1 
 
  
Discussion 
 
Our study did not show a statistically 
significant difference for cardiovascular mortality when 
comparing conventional therapy with treatment with 
beta blockers (p = 0.37), but there was a 34% risk 
reduction for mortality which, on the other hand, is of 
clinical relevance. Our results for mortality in patients 
with heart failure when treated with beta blockers are 
similar to those in the Cibis II study (treatment with 
Bisoprolol) [6]. Our therapy group showed a significant 
improvement in the combined outcome (p = 0.0008), 
RRR 40% and NNT 3.03, which is consistent mostly 
with the US Carvedilol Study where RRR% for the 
combined outcome was 38% [7-9]. 
In the analysis of the mortality and the 
combined outcome between the control group with 
each therapy subgroup separately, it appeared that 
the Metoprolol subgroup did not have a significant 
difference compared to the control group for mortality 
(p = 0.68) and RRR was 24%, but for the combined 
outcome, there was a statistically significant 
improvement (p = 0.0007), which is consistent with the 
MCD Study for Metoprolol where the mortality rate 
was also not significant (p = 0.69) [7].  
The Bisoprolol group also did not show a 
statistically significant difference for mortality 
compared to the control group (p = 0.58), RRR was 
30%, but it showed a significant difference for the 
combined outcome (p = 0.02) and was RRR 32%. 
This result differed from the CibisII study where the 
difference for the mortality was statistically significant, 
but CibisII study included larger number of patients 
and lasted longer (two and a half years) [6]. 
The Carvedilol subgroup compared to the 
control group did not show a significant difference in 
mortality (p = 0.220), but RRR was highest among all 
the subgroups, 56%, and there was also a significant 
reduction in the combined outcome (p = 0.007), RRR 
38%, which was consistent with the US Carvedilol 
Study where the RRR for the combined outcome was 
63% (p = 0.001) [8, 9].  
The meta-analysis of Chatterjee (BMJ, 2013) 
on the effect of beta-blockers showed that they 
reduced the mortality in heart failure patients, but as a 
result of their class effect. No specific beta blocker 
showed predominant effect upon risk reduction of 
mortality in chronic heart failure patients [9, 10].  
In conclusion, our study confirmed that 
patients with stable chronic heart failure, treated with 
optimal doses of beta-blockers, had a significant 
reduction of the risk from death as well as the 
combined outcome (death and/or number of 
hospitalizations). No specific beta-blocker surpasses 
the effect of the other beta-blockers in the treatment of 
chronic heart failure considering the risk reduction. 
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